NERV

Minerva Neurosciences

Fundamental data last updated:March 30, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/12/26

Business Summary

Minerva Neurosciences is a biotechnology company focused on developing therapies for central nervous system disorders. It works on clinical-stage drug candidates targeting unmet medical needs in areas such as psychiatric and neurological conditions.

 


Analyze NERV on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$267

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

-

EV / EBITDA

-0.6

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$34.67

Next Year EPS Growth Estimate

-$0.48

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

208.50%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

-

Piotroski F-Score

3

Altman Z-Score

-8.7

Return on Invested Capital (ROIC)

208.50%

Current Ratio

36.3

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze NERV on TradingView

Gainseekers Quantitative Analysis

Summary

Minerva Neurosciences is a Healthcare company in the Biotechnology industry listed on the Nasdaq with a market capitalization of $267 million. The company reports an EPS of -0.6, with EPS next year estimated at -$34.67 and sales growth next year projected at -$0.48. It shows an operating margin of 208.50%, while several valuation metrics such as P/E, Forward P/E, and Price/Sales are not available.

AI Exposure / Tech Reliance

As a biotechnology company, its operations are primarily research-driven rather than AI-focused. There is no specific data provided indicating direct AI exposure.

The Bull Case

The company’s reported operating margin of 208.50% may indicate favorable operating dynamics at this stage. With a consensus rating of 1.40% and a mean consensus target price of 3, there appears to be some level of analyst support.

The Bear Case

The company is currently unprofitable with an EPS of -0.6 and a sharply negative EPS estimate of -$34.67 for next year, alongside projected sales growth of -$0.48. The absence of key valuation metrics such as P/E and Price/Sales may reflect financial instability or limited revenue visibility.

Market Sentiment & Smart Money

Short Interest %

1.40%

Analyst Consensus

3

Average Analyst Price Target

$7.25

Institutional Ownership %

68.20%

1-Year Beta

0.59

Insider Buying % (6 Mo)

3.60%%

Distance to 52-Week High

49.70%

Distance to 52-Week Low

538.30%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.